Main navigation

• Home
• Our medicines
• Diseases and conditions
• Community support
• Help affording your medicines
• Research & development
• Healthcare professionals
• Careers
• About AstraZeneca US
  • Our company
  • AZ on the issues
  • Investors
  • Responsible business
  • Newsroom
    • All news
    • Corporate news
    • Financial news
    • Product news
    • Research news
    • Media resources
  • US web sites
  • Social media sites
  • Contact us

You are here

• Home
• About AstraZeneca US
• Newsroom

• News

The following shows headlines of all news articles published within 12-months, starting from most recent.

• Pages
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• Next

• • Feb 8, 2010
  • US FDA approves new indication for CRESTOR® (rosuvastatin calcium)  
• • Jan 28, 2010
  • AstraZeneca PLC fourth quarter and full year results 2009  
• • Jan 18, 2010
  • AstraZeneca and Dako sign agreement to develop companion diagnostics for cancer treatments  
• • Jan 13, 2010
  • AstraZeneca offers online enrollment and additional improvements to patient assistance program  
• • Dec 23, 2009
  • AstraZeneca makes contribution to Delaware Does More  
• • Dec 17, 2009
  • AstraZeneca details position on Comparative Effectiveness policy  
• • Dec 15, 2009
  • Favorable vote from FDA Advisory Committee on benefit/risk of CRESTOR® (rosuvastatin calcium) in JUPITER study  
• • Dec 15, 2009
  • AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease  
• • Dec 11, 2009
  • Advisory Committee briefing materials for CRESTOR® sNDA available on US FDA web site  
• • Dec 10, 2009
  • Phase III CONFIRM study shows FASLODEX® (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer  

• Pages
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• Next

Page tools

• Print
• Bookmark this page
• Subscribe to RSS news feed